About Pharmiva

About Pharmiva

Our vision is to transform treatment and relieve problems related to intimate infections and STIs globally.

Pharmiva is at the heart of Women’s Health while addressing the growing problem of Antimicrobial Resistance or AMR. Our technology platform is based on HPLA, a combination of naturally occurring compounds, excluding development of resistance. The technology is about non-antibiotic treatment of intimate infections, STIs and related symptoms while reinforcing the body’s natural defence system.

Based on our patent pending technology we develop a portfolio of pharmaceutical and consumer health category products.

In a concluded Phase I/II Proof-of-Concept study on BV patients we demonstrate strong efficacy and safety. Based on results showing 100% improvement in symptoms 1-2 weeks after treatment we are launching our first medical device category product. We estimate approval and market introduction for our first product in the beginning of 2018 and have a clear plan for continued clinical development of our portfolio of products.

Please contact us for full clinical results in our Scientific Clinical Study Report.

Our Focus

The transformative features of our technology platform allow us to address three main areas of unmet need that are exacerbated by globally increasing Antimicrobial Resistance (AMR)
1. Effective treatment of recurring BV

1. Effective treatment of recurring BV

300M women world-wide suffer from Bacterial Vaginosis. Recurrence rates post treatment are typically 30-50% and antibiotics is the only recommended curative treatment. BV is also viewed as a gateway for STIs.



2. Treatment of STIs subject to Antibiotic Resistance

2. Treatment of STIs subject to Antibiotic Resistance

Each year more than 450M people are infected by the most common Sexually Transmitted Indications (Gonorrhea, Chlamydia, Trichomonas). In Gonorrhea alone the number is 100M per year and is growing by 10% annually. Several strains of Gonorrhea bacteria are resistant and there is no effective treatment available.

3. Prophylactic treatment of BV and STIs

3. Prophylactic treatment of BV and STIs

Combining product safety, efficacy and exclusion of AMR, the technology opens the opportunity for preventive treatment of both BV and STIs. We believe that safe, prophylactic treatment of these indications will provide significant health benefits to millions of men and women world-wide.

Management Team

40+ years experience developing pharmaceuticals • Specializing in dermatology and drug delivery • C. 20 products in market or previously in market • More than 40 approved patents
Åke Lindahl
Åke Lindahl
Chairman, Head of Development
David Sagna
David Sagna
Head of Operations
Anna Holmberg
Anna Holmberg
Director Development & Regulatory Affairs
Malte Zaunders
Malte Zaunders
Managing Director

Advisors

Scientific • Commercial • IP Advisors

PG Larsson, Prof/MD

Clinical expert BV, Principal Investigator

John Balian, MD

Ex CMO J&J

Magnus Unemo, PhD

Director WHO, STI Expert

Anders Thorén, MD

MA TFS, Ex Clinical Dev Astra Zeneca

William King

Founder and Executive Chairman Zephyr Health

Jeff Melcher

Patent Attorney MDS Law

Philip Webber

Patent Attorney Dehns

Anders Williamsson

Ex CEO Hemocue

"Transforming treatment and relieving problems in intimate infections and STIs globally"